HR
VIRX

Howe & Rusling’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Howe & Rusling’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed – – 1079
2015
Q2 		$0 Buy
+1
New +$531 ﹤0.01% 1120

Other funds holding VIRX

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Howe & Rusling's VIRX Position: Q3 2015 in Review

Howe & Rusling sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 1 share.

Howe & Rusling first reported a position in VIRX in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

  • Howe & Rusling reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Howe & Rusling sold 1 Viracta Therapeutics, Inc. Common Stock share in Q3 2015.
  • Howe & Rusling first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Howe & Rusling's Viracta Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2015.
  • 59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Howe & Rusling's 13F filing for Q3 2015, filed 10 Nov 2015.